2.98
price down icon0.33%   -0.01
after-market 시간 외 거래: 2.98
loading
전일 마감가:
$2.99
열려 있는:
$3.02
하루 거래량:
551.04K
Relative Volume:
1.61
시가총액:
$247.32M
수익:
$351.37M
순이익/손실:
$-174.01M
주가수익비율:
-1.4396
EPS:
-2.07
순현금흐름:
$-126.94M
1주 성능:
+3.11%
1개월 성능:
+3.47%
6개월 성능:
-9.42%
1년 성능:
-22.19%
1일 변동 폭
Value
$2.9501
$3.08
1주일 범위
Value
$2.825
$3.08
52주 변동 폭
Value
$2.60
$4.145

Atea Pharmaceuticals Inc Stock (AVIR) Company Profile

Name
명칭
Atea Pharmaceuticals Inc
Name
전화
857-204-8109
Name
주소
225 FRANKLIN STREET, BOSTON
Name
직원
56
Name
트위터
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
AVIR's Discussions on Twitter

AVIR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
AVIR
Atea Pharmaceuticals Inc
2.98 247.32M 351.37M -174.01M -126.94M -2.07
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
501.15 126.96B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.61 65.06B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
649.67 37.54B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.39 32.56B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
255.77 26.40B 3.81B -644.79M -669.77M -6.24

Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-08-13 업그레이드 Morgan Stanley Underweight → Equal-Weight
2023-08-10 다운그레이드 JP Morgan Neutral → Underweight
2022-01-06 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2021-11-18 다운그레이드 SVB Leerink Outperform → Mkt Perform
2021-10-20 다운그레이드 JP Morgan Overweight → Neutral
2021-10-05 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-11-25 개시 Evercore ISI Outperform
2020-11-24 개시 JP Morgan Overweight
2020-11-24 개시 Morgan Stanley Overweight
2020-11-24 개시 William Blair Outperform
모두보기

Atea Pharmaceuticals Inc 주식(AVIR)의 최신 뉴스

pulisher
May 01, 2025

A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times

May 01, 2025
pulisher
Apr 26, 2025

JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX

Apr 25, 2025
pulisher
Apr 23, 2025

Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan

Apr 23, 2025
pulisher
Apr 22, 2025

A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News

Apr 22, 2025
pulisher
Apr 22, 2025

Layoff Tracker: Tempest Axes 80% of Workforce - BioSpace

Apr 22, 2025
pulisher
Apr 18, 2025

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada

Apr 17, 2025
pulisher
Apr 17, 2025

Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire

Apr 17, 2025
pulisher
Apr 17, 2025

Atea Pharma Doubles Down: $25M Share Buyback Plan Unveiled as Strategic Review Accelerates - Stock Titan

Apr 17, 2025
pulisher
Apr 13, 2025

Morgan Stanley Issues Pessimistic Forecast for Atea Pharmaceuticals (NASDAQ:AVIR) Stock Price - Defense World

Apr 13, 2025
pulisher
Apr 11, 2025

Atea Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:AVIR - Benzinga

Apr 11, 2025
pulisher
Apr 10, 2025

Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study - MSN

Apr 10, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Doses First Patient In Phase 3 Trial For Chronic Hepatitis C Treatment - RTTNews

Apr 09, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Doses First Patient in Late-Stage Study of Hepatitis C Virus Combination Regimen - marketscreener.com

Apr 09, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Announces Dosing of First Patient in - GlobeNewswire

Apr 09, 2025
pulisher
Apr 09, 2025

Atea Pharmaceuticals Announces Dosing Of First Patient In C-Beyond, Phase 3 Study Evaluating Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

Breakthrough: Atea's New 8-Week Hepatitis C Treatment Enters Final Trial Stage - Stock Titan

Apr 09, 2025
pulisher
Apr 05, 2025

HighTower Advisors LLC Purchases Shares of 50,087 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Apr 05, 2025
pulisher
Apr 01, 2025

Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting - Investing.com

Apr 01, 2025
pulisher
Mar 31, 2025

Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - The Manila Times

Mar 31, 2025
pulisher
Mar 29, 2025

Charles Schwab Investment Management Inc. Boosts Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Mar 29, 2025
pulisher
Mar 26, 2025

Atea Pharmaceuticals takes steps to boost shareholder value By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Atea Pharmaceuticals takes steps to boost shareholder value - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Atea Pharma Reviewing Strategic Opportunities After Cutting 25% of Jobs - MarketWatch

Mar 26, 2025
pulisher
Mar 26, 2025

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - The Manila Times

Mar 26, 2025
pulisher
Mar 26, 2025

Atea's Bold Restructuring: $15M Cost Savings Plan and Strategic Review Unveiled - Stock Titan

Mar 26, 2025
pulisher
Mar 26, 2025

Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting - Marketscreener.com

Mar 26, 2025
pulisher
Mar 26, 2025

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - MarketScreener

Mar 26, 2025
pulisher
Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World

Mar 24, 2025
pulisher
Mar 22, 2025

Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewswire

Mar 22, 2025
pulisher
Mar 21, 2025

Atea Pharmaceuticals receives notice of director nominations from Bradley Radoff -March 21, 2025 at 05:58 pm EDT - MarketScreener

Mar 21, 2025

Atea Pharmaceuticals Inc (AVIR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$72.30
price down icon 0.47%
$21.48
price up icon 2.63%
$32.89
price up icon 1.26%
$27.90
price up icon 13.09%
$104.94
price up icon 2.45%
biotechnology ONC
$255.77
price up icon 0.05%
자본화:     |  볼륨(24시간):